Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Telecoms

Broker cheers BATM Advanced Communications strong balance sheet and big opportunities

“Strong underlying operating development is now visible," says analyst Robin Speakman

Shore Capital sees positive ‘long-term upgrade potential’ for BATM Advanced Communications Ltd (LSE:BVC) which today released upbeat interim results.

“With a strong balance sheet, BATM is addressing large market opportunities demanding technology-based solutions with clients and partners keen to tap into its emerging technologies,” Shore Capital analyst Robin Speakman said in a note.

“Strong underlying operating development is now visible across both Networking & Cyber and Bio-Medical (which includes Diagnostics) divisions.“

BATM this morning said that the full-year outcome is expected to be significantly ahead of market expectations, driven by demand for its high-margin diagnostic solutions.

The provider of real-time technologies for networking solutions and medical laboratory systems managed to grow underlying earnings (EBITDA) by 325% in the first half of 2021 despite a dip in revenue.

EBITDA jumped to US$22.7mln from US$5.3mln in the first half of 2020 even after a 7.7% slide in revenue to US$71.4mln from US$77.4mln the year before. Profit before tax soared to US$19.8mln from US$1.9mln the previous year.

The Bio-Medical division accounted for 77.1% of total revenue, up from 64.6% the year before, as its turnover increased by 10.2% to US$55.1mln from US$50.0mln, driven by sales of COVID-19 diagnostic kits, which more than offset the contribution to revenues in the first half of last year from the exceptional critical care ventilators contract; stripping out the ventilator contract, revenues surged 36.4% year-on-year.

In the Networking and Cyber division, revenues tumbled to US$16.4mln from US$27.4mln the year before, largely reflecting the sale of the group's non-core NG Soft Ltd subsidiary in March 2021. Excluding NG Soft, revenue dipped to US$9.1mln from the previous year’s US$9.4mln.

Chief executive Zvi Marom said: “Looking ahead, we entered the second half with a strong order book and receiving sustained demand for our diagnostic solutions. We also continue to expect to generate revenue this year from the roll-out of Edgility OS by PCCW Global.”

“As a result, we anticipate achieving better-than-expected revenue for the full year and EBITDA to be substantially ahead of market expectations with growth of over 40% year-on-year. Consequently, and supported by a robust balance sheet, the board of BATM continues to look to the future with great confidence.”

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK